



**Grant Number:** 5U01CA033193-28

**Principal Investigator(s):**  
Vincent J Cogliano, PHD

**Project Title:** Evaluation of Carcinogenic Risks to Humans

Peter Boyle  
DIRECTOR, DIV OF ADMIN & FINANCE  
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER  
150, COURS ALBERT THOMAS  
69372 LYON CEDEX 08  
LYON CEDEX,  
FRANCE

**Award e-mailed to:** daf@iarc.fr

**Budget Period:** 09/01/2009 – 08/31/2010  
**Project Period:** 09/01/1985 – 08/31/2010

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$809,615 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Award Number U01CA033193 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health."

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to subgrantees, contractors, or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/coi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Galen Gregor  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

---

**SECTION I – AWARD DATA – 5U01CA033193-28****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$424,200
Fringe Benefits	\$141,300
Personnel Costs (Subtotal)	\$565,500
Consultant Services	\$35,398
Travel Costs	\$2,100
Other Costs	\$115,652

Federal Direct Costs	\$718,650
Federal F&A Costs	\$93,424
Approved Budget	\$812,074
Federal Share	\$812,074
Less Unobligated Balance	\$2,459
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$809,615</b>

<b>AMOUNT OF THIS ACTION (FEDERAL SHARE)</b>	<b>\$809,615</b>
--	------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
28	\$809,615	\$809,615

**Fiscal Information:**

CFDA Number:	93.393
EIN:	1900210016A1
Document Number:	UCA033193F
Fiscal Year:	2009

IC	CAN	2009
CA	8479565	\$809,615

**NIH Administrative Data:****PCC:** 9QCG3126 / **OC:** 414P / **Processed:** GREGORG 07/06/2009

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-28**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 5U01CA033193-28**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. Therefore, see the NIH Grants Policy Statement (12/1/2003 version) for closeout requirements at: [http://grants.nih.gov/grants/policy/nihgps\\_2003/NIHGPS\\_Part8.htm#\\_Toc54600151](http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part8.htm#_Toc54600151).

A final Financial Status Report (FSR) (SF 269) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see NIH Guide Notice [NOT-OD-07-078](#) for additional information on this electronic submission requirement.

Furthermore, unless an application for competitive renewal is submitted, additional grant closeout documents consisting of a Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) and a final progress report must also be submitted within 90 days of the expiration date.

NIH also strongly encourages electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons. If the final progress report and final invention statement are not submitted electronically, copies of the HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>.

Submissions of the final progress report and HHS 568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: [deascentralized@od.nih.gov](mailto:deascentralized@od.nih.gov)

Paper submissions of the final progress report and the HHS 568 may be faxed to the NIH Central Closeout Center at 301-480-2304 or mailed to the NIH Central Closeout Center at the following address:

NIH/OD/OER/DEAS  
Central Closeout Center  
6705 Rockledge Drive, Room 2207  
Bethesda, MD 20892-7987 (for regular or U.S. Postal Service Express mail)  
Bethesda, MD 20817 (for other courier/express mail delivery only)

The final progress report should include, at a minimum, a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative), a list of publications and the grant number. If human subjects were included in the research, the final progress report should also address the following:

- Report on the inclusion of gender and minority study subjects (using the gender and minority Inclusion Enrollment Form as provided in the PHS 2590 and available at <http://grants.nih.gov/grants/forms.htm>).
- Where appropriate, indicate whether children were involved in the study or how the study was relevant for conditions affecting children (see "Public Policy Requirements and Objectives-Requirements for Inclusiveness in Research Design-Inclusion of Children as Subjects in Clinical Research" in the PHS 398 at URL [http://grants.nih.gov/grants/policy/nihgps\\_2003/NIHGPS\\_Part5.htm#\\_Toc54600090](http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part5.htm#_Toc54600090)).
- Describe any data, research materials (such as cell lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be shared with other investigators and how it may be accessed.

Note, if this is the final year of a competitive segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable. Specifically a Final Progress Report is not required. However, a final FSR is required and should be submitted electronically as noted above. In addition, if not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

**Treatment of Program Income:**  
Additional Costs

---

## SECTION IV – CA Special Terms and Conditions – 5U01CA033193-28

**INFORMATION** This award is issued as a Cooperative Agreement, a financial assistance mechanism which requires cooperation between the awardee and the National Cancer Institute (NCI). The following Terms of Cooperation include the Programmatic Responsibilities of the Grantees, the Nature of Assistance by NCI Staff, Collaborative Responsibilities, and Arbitration Procedures (Attachment 1).

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

The following administrative terms also apply:

**RESTRICTION** This supplemental award provides \$47,607 (\$42,130 direct costs and \$5,477 associated facilities and administrative costs) to replace the support for the publication of IARC Monographs that was lost with the discontinuance of the support contract to TRI, as requested in the awardee's letter dated May 31, 2007. These funds are restricted and may not be expended for any other purpose without the written prior approval of the National Cancer Institute. Funds awarded are available for carryover for awards given carryover authority as reflected in section III of this award notice. However, the funds remain restricted for the purpose for which the supplement is awarded.

**INFORMATION** This award utilizes as an offset the unobligated balance from the -26 year financial status report.

**INFORMATION** In a continuing effort to provide exceptional customer service, the NCI Grants Administration Branch has set up a Feedback address on its web site (<http://www.nci.nih.gov/admin/gab/index.htm>). General concerns and issues related to NCI grants policies, procedures, and practices can be sent to the Customer Liaison using this feature. Specific questions or concerns related to this grant should be addressed to the Grants Management Specialist listed in the Terms of Award.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Joy Kearse  
**Email:** kearsej@mail.nih.gov **Phone:** 301-846-1010

**Program Official:** Alan P. Poland  
**Email:** polanda@mail.nih.gov **Phone:** (301) 496-1625 **Fax:** (301) 496-1040

**SPREADSHEET SUMMARY**

**GRANT NUMBER:** 5U01CA033193-28

**INSTITUTION:** INTERNATIONAL AGENCY FOR RES ON CANCER

<i>Budget</i>	<i>Year 28</i>
Salaries and Wages	\$424,200
Fringe Benefits	\$141,300
Personnel Costs (Subtotal)	\$565,500
Consultant Services	\$35,398
Travel Costs	\$2,100
Other Costs	\$115,652
TOTAL FEDERAL DC	\$718,650
TOTAL FEDERAL F&A	\$93,424
TOTAL COST	\$809,615





**Grant Number:** 5U01CA033193-28 REVISED

**Principal Investigator(s):**  
Vincent J Cogliano, PHD

**Project Title:** Evaluation of Carcinogenic Risks to Humans

Peter Boyle  
DIRECTOR, DIV OF ADMIN & FINANCE  
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER  
150, COURS ALBERT THOMAS  
69372 LYON CEDEX 08  
LYON CEDEX,  
FRANCE

**Award e-mailed to:** igo@iarc.fr

**Budget Period:** 09/01/2009 – 08/31/2010  
**Project Period:** 09/01/1985 – 08/31/2010

Dear Business Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Award Number U01CA033193 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health."

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to subgrantees, contractors, or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/coi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Joy Kearse  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

**SECTION I – AWARD DATA – 5U01CA033193-28 REVISED****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$424,200
Fringe Benefits	\$141,300
Personnel Costs (Subtotal)	\$565,500
Consultant Services	\$35,398
Travel Costs	\$2,100
Other Costs	\$120,338

Federal Direct Costs	\$723,336
Federal F&A Costs	\$93,424
Approved Budget	\$816,760
Federal Share	\$816,760
Less Unobligated Balance	\$7,145
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$809,615</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE) \$0**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
28	\$809,615	\$809,615

**Fiscal Information:**

CFDA Number: 93.393  
 EIN: 1900210016A1  
 Document Number: UCA033193F  
 Fiscal Year: 2009

	IC	CAN	2009
CA		8479565	\$809,615

**NIH Administrative Data:**

PCC: 9QCG3126 / OC: 414P / Processed: KEARSEJ 08/26/2010

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-28 REVISED**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

**SECTION III – TERMS AND CONDITIONS – 5U01CA033193-28 REVISED**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. Therefore, see the NIH Grants Policy Statement (12/1/2003 version) for closeout requirements at: [http://grants.nih.gov/grants/policy/nihgps\\_2003/NIHGPS\\_Part8.htm#\\_Toc54600151](http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part8.htm#_Toc54600151).

A final Financial Status Report (FSR) (SF 269) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see NIH Guide Notice [NOT-OD-07-078](#) for additional information on this electronic submission requirement. The final FSR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FSR and the Payment Management System's (PMS) Federal Cash Transaction Report (SF-272).

Furthermore, unless an application for competitive renewal is submitted, additional grant closeout documents consisting of a Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) and a final progress report must also be submitted within 90 days of the expiration date.

NIH also strongly encourages electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons. If the final progress report and final invention statement are not submitted electronically, copies of the HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>.

Submissions of the final progress report and HHS 568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: [deascentralized@od.nih.gov](mailto:deascentralized@od.nih.gov)

Paper submissions of the final progress report and the HHS 568 may be faxed to the NIH Central Closeout Center at 301-480-2304 or mailed to the NIH Central Closeout Center at the following address:

NIH/OD/OER/DEAS  
Central Closeout Center  
6705 Rockledge Drive, Room 2207  
Bethesda, MD 20892-7987 (for regular or U.S. Postal Service Express mail)  
Bethesda, MD 20817 (for other courier/express mail delivery only)

The final progress report should include, at a minimum, a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative), a list of publications and the grant number. If human subjects were included in the research, the final progress report should also address the following:

- Report on the inclusion of gender and minority study subjects (using the gender and minority Inclusion Enrollment Form as provided in the PHS 2590 and available at <http://grants.nih.gov/grants/forms.htm>).
- Where appropriate, indicate whether children were involved in the study or how the study was relevant for conditions affecting children (see "Public Policy Requirements and Objectives-Requirements for Inclusiveness in Research Design-Inclusion of Children as Subjects in Clinical Research" in the PHS 398 at URL [http://grants.nih.gov/grants/policy/nihgps\\_2003/NIHGPS\\_Part5.htm#\\_Toc54600090](http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part5.htm#_Toc54600090))
- Describe any data, research materials (such as cell lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be shared with other investigators and how it may be accessed.

Note, if this is the final year of a competitive segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable. Specifically a Final Progress Report is not required. However, a final FSR is required and should be submitted electronically as noted above. In addition, if not already submitted, the Final Invention Statement is required and should be sent directly the assigned Grants Management Specialist.

---

**SECTION IV – CA Special Terms and Conditions – 5U01CA033193-28 REVISED**

**INFORMATION** This award is issued as a Cooperative Agreement, a financial assistance mechanism which requires cooperation between the awardee and the National Cancer Institute (NCI). The following Terms of Cooperation include the Programmatic Responsibilities of the Grantees, the Nature of Assistance by NCI Staff, Collaborative Responsibilities, and Arbitration Procedures (Attachment 1).

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

The following administrative terms also apply:

**RESTRICTION:** This revised award authorizes a carryover of \$4,686 in unexpended funds from the 27-year to be used in the 28- year as requested in the awardee's letter dated August 20, 2010.

**THE FOLLOWING TERMS FROM THE PREVIOUS NOTICE OF GRANT AWARD ISSUED ON 7/7/09 ALSO APPLY TO THIS AWARD:**

**RESTRICTION** This supplemental award provides \$47,607 (\$42,130 direct costs and \$5,477 associated facilities and administrative costs) to replace the support for the publication of IARC Monographs that was lost with the discontinuance of the support contract to TRI, as requested in the awardee's letter dated May 31, 2007. These funds are restricted and may not be expended for any other purpose without the written prior approval of the National Cancer Institute. Funds awarded are available for carryover for awards given carryover authority as reflected in section III of this award notice. However, the funds remain restricted for the purpose for which the supplement is awarded.

**INFORMATION** This award utilizes as an offset the unobligated balance from the -26 year financial status report.

**INFORMATION** In a continuing effort to provide exceptional customer service, the NCI Grants Administration Branch has set up a Feedback address on its web site (<http://www.nci.nih.gov/admin/gab/index.htm>). General concerns and issues related to NCI grants policies, procedures, and practices can be sent to the Customer Liaison using this feature. Specific questions or concerns related to this grant should be addressed to the Grants Management Specialist listed in the Terms of Award.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Joy Kearse  
**Email:** kearsej@mail.nih.gov **Phone:** 301-846-1010

**Program Official:** Alan P. Poland  
**Email:** polanda@mail.nih.gov **Phone:** (301) 496-1625 **Fax:** (301) 496-1040

**SPREADSHEET SUMMARY**

**GRANT NUMBER:** 5U01CA033193-28 REVISED

<b>Budget</b>	<b>Year 28</b>
Salaries and Wages	\$424,200
Fringe Benefits	\$141,300
Personnel Costs (Subtotal)	\$565,500
Consultant Services	\$35,398
Travel Costs	\$2,100
Other Costs	\$120,338
TOTAL FEDERAL DC	\$723,336
TOTAL FEDERAL F&A	\$93,424
TOTAL COST	\$809,615

**Progress Report Scanning Cover Sheet**

**5U01CA033193-28**

PI Name: **COGLIANO, VINCENT**  
Org: **INTERNATIONAL AGENCY FOR RES ON  
CANCER**  
Start Date: **09/01/2009**  
Snap: **N/A (NEEDS TO BE BOOKMARKED)**  
Appl ID: **7673386**  
Rec'd  
Date: **06/29/2009**

Department of Health and Human Services  
Public Health Services

Review Group	Type 5	Activity U01	Grant Number 5U01CA033193-27 28
Total Project Period			
From: 09/01/1985		Through: 08/31/2010	
Requested Budget Period			
From: 09/01/2009		Through: 08/31/2010	

**Grant Progress Report**

1. TITLE OF PROJECT Evaluation of Carcinogenic Risks to Humans		
2a. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR (Name and address, street, city, state, zip code) Vincent James Cogliano Section of IARC Monographs International Agency for Research on Cancer 150, Cours Albert Thomas F-69372 Lyon cedex 08, France		2b. E-MAIL ADDRESS imo@iarc.fr
		2c. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT Section of IARC Monographs
		2d. MAJOR SUBDIVISION Section of IARC Monographs
		2e. Tel: 33-4-72.72.84.76 Fax: 33-4-72.72.83.19
3a. APPLICANT ORGANIZATION (Name and address, street, city, state, zip code) International Agency for Research on Cancer 150, Cours Albert Thomas F-69372 Lyon cedex 08, France		3b. Tel: 33-4-72.73.84.85 Fax: 33-4-72.73.85.75
		3c. DUNS: 279551881
		4. ENTITY IDENTIFICATION NUMBER 1900210016A1 JUN 2 2009
6. HUMAN SUBJECTS <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	5. NAME, TITLE AND ADDRESS OF ADMINISTRATIVE OFFICIAL Olaf Kelm, External Relations Officer, International Agency for Research on Cancer, 150 Cours Albert Thomas, F-69372 Lyon cedex 08, France	
6a. Research Exempt <input type="checkbox"/> No <input type="checkbox"/> Yes	If Exempt ("Yes" in 6a): Exemption No.	If Not Exempt ("No" in 6a): IRB approval date
6b. Federal Wide Assurance No.	Tel: 33-472-73.84.94 Fax: 33-472-73.85.64	
6c. NIH-Defined Phase III Clinical Trial <input type="checkbox"/> No <input type="checkbox"/> Yes	E-MAIL: igo@iarc.fr	
7. VERTEBRATE ANIMALS <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	10. PROJECT/PERFORMANCE SITE(S) Organizational Name: Int. Agency for Research on Cancer DUNS: 279551881	
7a. If "Yes," IACUC approval Date		
7b. Animal Welfare Assurance No.		
8. COSTS REQUESTED FOR NEXT BUDGET PERIOD		
8a. DIRECT \$718,649	8b. TOTAL \$812,074	
Street 1: 150 Cours Albert Thomas		
Street 2:		
9. INVENTIONS AND PATENTS <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		City: Lyon
If "Yes," <input type="checkbox"/> Previously Reported <input type="checkbox"/> Not Previously Reported		County:
		State:
		Province:
		Country: France
		Zip/Postal Code: 69372 cedex08
Congressional Districts:		
11. NAME AND TITLE OF OFFICIAL SIGNING FOR APPLICANT ORGANIZATION (Item 13) Cristopher P. Wild, Director		
TEL: 33-472-73.85.77	FAX: 33-472-73.85.64	E-MAIL: director@iarc.fr
12. Corrections to Page 1 Face Page		
13. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.		11. (In ink) Signature Cristopher P. Wild
		DATE 24.6.09

Program Director/Principal Investigator (Last, First, Middle): **COGLIANO, Vincent James**

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY		FROM 09/01/2009			THROUGH 08/31/2010		GRANT NUMBER 5U01CA033193-27	
PERSONNEL (Applicant organization only)		Months Devoted to Project			DOLLAR AMOUNT REQUESTED (omit cents)			
NAME	ROLE ON PROJECT	Cal. Mnth	Acad. Mnth	Summer Mnth	SALARY REQUESTED	FRINGE BENEFITS	TOTALS	
COGLIANO, V.J.	PD/PI	(b)(4), (b)(6)			0	0	0	
EL GHISSASSI, F.	Scientist				81,850	27,250	109,100	
GALICHET, L.	Scientist				78,100	26,000	104,100	
P2 IARC Scientist *	Scientist	12			85,450	28,450	113,900	
P2 IARC Scientist *	Scientist	12			81,000	27,000	108,000	
P1 IARC Scientist *	Scientist	7			33,600	11,200	44,800	
EGRAZ, S.	Archivist	(b)(4), (b)(6)			64,200	21,400	85,600	
<b>SUBTOTALS</b> →					<b>424,200</b>	<b>141,300</b>	<b>565,500</b>	
CONSULTANT COSTS See page 3							35,398	
EQUIPMENT ( <i>Itemize</i> )								
SUPPLIES ( <i>Itemize by category</i> )								
TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials							2,100	
PATIENT CARE COSTS		INPATIENT						
		OUTPATIENT						
ALTERATIONS AND RENOVATIONS ( <i>Itemize by category</i> )								
OTHER EXPENSES ( <i>Itemize by category</i> ) See page 3							115,651	
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>\$ 718,649</b>	
CONSORTIUM/CONTRACTUAL COSTS		DIRECT COSTS						
		FACILITIES AND ADMINISTRATIVE COSTS						
<b>TOTAL DIRECT COSTS FOR NEXT PROJECT PERIOD (<i>Item 8a, Face Page</i>)</b>							<b>\$ 718,649</b>	

Program Director/Principal Investigator (Last, First, Middle): **COGLIANO, Vincent James**

**BUDGET JUSTIFICATION**

GRANT NUMBER  
5U01CA033193-27

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

**CONSULTANT :**

In accordance with the payment schedule on IARC's contract with Technical Resources International Inc, to remain within the limits of the recommended support for year 28 of the grant, and to ensure the funding for one working group and printing of one volume, only the funds scheduled to be paid to TRI Inc. during the budget period for year 28 are included here.

No honorarium will be paid to experts for the preparation of draft monographs and the editing work will be funded by other sources.

**OTHER :**

- Working group (\$100,000 X 1)	\$100,000
- Printing of Monograph (\$15,000 X 1)	\$ 15,000
- Books, journals and reproduction costs	\$ 651
	-----
	\$115,651

**\* PERSONNEL :**

The 2 P2 and the P1 IARC Scientist posts are currently occupied by Dr Tallaa L., Dr Bouvard V., and Dr Guha N.

**CURRENT BUDGET PERIOD**

FROM  
09/01/2008

THROUGH  
08/31/2009

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure -----	Estimated unobligated balance -----
DIRECT COSTS	\$698,942	\$0
INDIRECT COSTS	\$ 90,863	\$0
	-----	
<b>TOTAL COSTS</b>	<b>\$789,805</b>	<b>\$0</b>

**Other Active Support**

(b)(4), (b)(6) 01/01/09-12/31/09 \$84,000

No overlap with the NCI cooperative agreement. Funds used to support the 3<sup>rd</sup> Monographs meeting each year and scientific or advisory meetings relevant to the Monographs Programme.

NIEHS \$100,000  
Funds used to support document-production activities and temporary staffing of the Monographs programme.

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>BOUVARD, Veronique</b>		POSITION TITLE Scientific specialist	
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Universite Claude Bernard Lyon I (France)	Maitrise	1982	Cellular Biology
Universite Claude Bernard Lyon I (France)	DEA	1983	Microbiological Ecology
Universite Claude Bernard Lyon I (France)	CES	1984	General Immunology
Universite Claude Bernard Lyon I (France)	Doctorat	1987	Microbiology

**A. Positions and Honors**

**1987-1989:** Post –Doctoral training, Laboratoire de Culture cutanee, Hopital St sacrament, Quebec, Canada

**1990-1997:** Junior Scientist, International Centre for Genetic Engineering and biotechnology (ICGEB) initially part of UNIDO (United Nations Industrial Development Organization), "Virology group", Padriciano, Trieste, Italy.

**1997-2000:** Researcher in Molecular Biology, "Laboratoire de Cancerogenese Moleculaire", CEA/CNRS, CEN Fontenay aux Roses, France.

**2001-2002 :** Researcher in Molecular Biology, "Molecular Engines Laboratories", Paris, France.

**2003-2004:** Scientific specialist, "Carcinogen Identification and Evaluation" Group, IARC, Lyon, France.

**2004-2006:** Scientific specialist, "Infections and Cancer Biology" Group, IARC, Lyon, France.

**2006-** Scientific specialist, "Carcinogen Identification and Evaluation" Group, IARC, Lyon, France.

**B. Selected peer-reviewed publications (in chronological order)**

1. Freney J, Garonnat D, Bouvard V, et al. (1984). [Comparison of 2 systems for identifying nonfermenting or fermenting oxidase-positive gram-negative bacilli]. *Ann Biol Clin (Paris)*, 42(5):337-341.
2. Bouvard V, Chardonnet Y, Viac J (1986). The use of in situ hybridization technique for papillomavirus DNA detection in human pathology. *Microbios Letters*, 32:147-155.
3. Chardonnet Y, Viac J, Bouvard V, et al. (1986). Markers of epithelial cell activation and virus expression in cutaneous and mucosal papillomas. *J Invest Dermatol*, 87(1):133.
4. Bouvard V, Viac J, Chardonnet Y, et al. (1987). Mucous and cutaneous papillomas, a study of viral-DNA by in situ hybridization and local immune reactions. *Ann Dermatol Venereol*, 114(3):469.
5. Chardonnet Y, Bouvard V, Gilgenkrantz H, et al. (1987). A method of in situ molecular hybridization applied to the study of viral papillomas in man. *Ann Dermatol Venereol*, 114(12):1507-1516.
6. Chardonnet Y, Bouvard V, Gilgenkrantz H, et al. (1987). In situ hybridization in human papilloma investigations. *Ann Dermatol Venereol*, 114(12):1507-1516.
7. Chardonnet Y, Bouvard V, Gilgenkrantz H, et al. (1987). In situ molecular hybridization used in the study of human viral papillomas. *Ann Dermatol Venereol*, 114(4):634.
8. Viac J, Chardonnet Y, Bouvard V, et al. (1987). Virus expression. EGF and transferrin receptors in human papillomas. *Virchows Arch A Pathol Anat Histopathol*, 411(1):73-77.
9. Rompre P, Auger FA, Germain L, et al. (1990). Influence of initial collagen and cellular concentrations on the final surface area of dermal and skin equivalents: a Box-Behnken analysis. *In Vitro Cell Dev Biol*, 26(10):983-990.

Program Director/Principal Investigator (Last, First, Middle): COGLIANO, Vincent James

10. Bouvard V, Germain L, Rompre P, et al. (1992). Influence of dermal equivalent maturation on the development of a cultured skin equivalent. *Biochem Cell Biol*, 70(1):34-42.
11. Lopez Valle CA, Auger FA, Rompre P, et al. (1992). Peripheral anchorage of dermal equivalents. *Br J Dermatol*, 127(4):365-371.
12. Germain L, Rouabhia M, Guignard R, et al. (1993). Improvement of human keratinocyte isolation and culture using thermolysin. *Burns*, 19(2):99-104.
13. Bouvard V, Matlashewski G, Gu ZM, et al. (1994). The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. *Virology*, 203(1):73-80.
14. Bouvard V, Storey A, Pim D, et al. (1994). Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. *EMBO J*, 13(22):5451-5459.
15. Bouvard V, Sexton C (1994). Stable transfection of human keratinocytes: HPV immortalization. In: Irene Leigh FW, ed., *Keratinocyte Methods*. Cambridge, Cambridge University Press: 179-180.
16. Bouvard V, Banks L (1994). Characterization of factors involved in human papillomavirus type 16-mediated immortalization: potential for antiviral chemotherapy. *International Antiviral News*, 2:40-42.
17. Navsaria H, Sexton C, Bouvard V (1994). Growth of keratinocytes with 3T3 feeder layer: basic techniques. In: Irene Leigh FW, ed., *Keratinocyte Methods*. Cambridge, Cambridge University Press: 5-12.
18. Storey A, Piccini A, Massimi P, et al. (1995). Mutations in the human papillomavirus type 16 E2 protein identify a region of the protein involved in binding to E1 protein. *J Gen Virol*, 76 ( Pt 4):819-826.
19. Bouvard V, Massimi P, Banks L (1996). Characterization of cellular factors which influence progression of human papillomavirus type 16 immortalised keratinocytes to anchorage-independence. *Int J Oncol*, 8:159-167.
20. Straif K, Silverstein M (1997). Comparison of U.S. Occupational Safety and Health Administration standards and German Berufsgenossenschaften Guidelines for Preventive Occupational Health Examinations. *Am J Ind Med*, 31(4):373-380.
21. Massimi P, Pim D, Bertoli C, et al. (1999). Interaction between the HPV-16 E2 transcriptional activator and p53. *Oncogene*, 18(54):7748-7754.
22. Bouvard V, Zaitchouk T, Vacher M, et al. (2000). Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. *Oncogene*, 19(5):649-660.
23. Drane P, Bravard A, Bouvard V, et al. (2001). Reciprocal down-regulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis. *Oncogene*, 20(4):430-439.
24. Straif K (2001). Meta-analysis of risk estimates for prostate cancer among rubber workers. *J Occup Environ Med*, 43(7):593-595.
25. Passer BJ, Nancy-Portebois V, Amzallag N, et al. (2003). The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. *Proc Natl Acad Sci U S A*, 100(5):2284-2289.
26. Alvarez S, Drane P, Meiller A, et al. (2006). A comprehensive study of p53 transcriptional activity in thymus and spleen of gamma irradiated mouse: high sensitivity of genes involved in the two main apoptotic pathways. *Int J Radiat Biol*, 82(11):761-770.
27. Baan R, Straif K, Grosse Y, et al. (2006). Carcinogenicity of carbon black, titanium dioxide, and talc. *Lancet Oncol*, 7(4):295-296.
28. Bouvard V, Gabet A, Accardi R, et al. (2006). The Cutaneous Human Papillomavirus types and Non-melanoma Skin Cancer. In: M.Saveria Campo, ed., *From Natural History to Vaccines and Beyond*. Caister Academic Press: 269-277.
29. Baan R, Straif K, Grosse Y, et al. (2007). Carcinogenicity of alcoholic beverages. *Lancet Oncol*, 8(4):292-293.
30. Bouvard V, Accardi R, Hasan UA, et al. (2007). Transcriptional regulation of beta human papillomavirus genes and the impact of their products on cellular protein levels. In: Bodil Norrild, ed., *Human Papillomavirus Gene Regulation and Transformation*. Kerala, India, Transworld Research Network: 203-224.
31. Grosse Y, Baan R, Straif K, et al. (2007). Carcinogenicity of 1,3-butadiene, ethylene oxide, vinyl chloride, vinyl fluoride, and vinyl bromide. *Lancet Oncol*, 8(8):679-680.

Program Director/Principal Investigator (Last, First, Middle): COGLIANO, Vincent James

32. Guerrini JS, Bouvard V, Oswald E, et al. (2007). E6 and E7 from different beta-HPV do not interfere in HaCat cells UVB-induced apoptosis . *Bulletin du Cancer*, 94(6):616.
33. Guerrini JS, Bouvard V, Oswald E, et al. (2007). E6 and E7 from different beta-HPV do not interfere in UVB-induced Apoptosis of HaCaT cells. *J Invest Dermatol*, 127(10):2477.
34. Hasan UA, Bates E, Takeshita F, et al. (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. *J Immunol*, 178(5):3186-3197.
35. Straif K, Baan R, Grosse Y, et al. (2007). Carcinogenicity of shift-work, painting, and fire-fighting. *Lancet Oncol*, 8:1065-1066.
36. Baan R, Straif K, Grosse Y, et al. (2008). Carcinogenicity of some aromatic amines, organic dyes, and related exposures. *Lancet Oncol*, 9(4):322-323.
37. Baan R, Straif K, Grosse Y, et al. (2008). Carcinogenicity of some aromatic amines, organic dyes, and related exposures. *Lancet Oncol*, 9(4):322-323.
38. Cogliano V, Baan R, Straif K, et al. (2008). Future priorities for IARC monographs. *Lancet Oncol*, 9(8):708.
39. Cordano P, Gillan V, Bratlie S, et al. (2008). The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. *Virology*, 377(2):408-418.
40. Massimi P, Thomas M, Bouvard V, et al. (2008). Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer. *Virology*, 371(2):374-379.
41. Morandell D, Rostek U, Bouvard V, et al. (2008). Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression. *Virology*, 379(1):20-29.
42. Bouvard V, Baan R, Straif K, et al. (2009). A review of human carcinogens--Part B: biological agents. *Lancet Oncol*, 10(4):321-322.
43. Straif K, Benbrahim-Tallaa L, Baan R, et al. (2009). A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. *Lancet Oncol*, 10(5):453-454.

### C. Research Support

None

**BIOGRAPHICAL SKETCH**Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>FREEMAN, Crystal M.</b>		POSITION TITLE Research Scientist	
eRA COMMONS USER NAME <b>(b) (4)</b>			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Toronto, Toronto, Canada	Ph.D.	2003	Epidemiology
San Diego State University, San Diego, CA	M.P.H	1994	Health Promotion
University of California, Davis, CA	B.S.	1990	Biopsychology

**A. Positions and Honors****Positions and Employment**

1992-1994	Graduate Assistant, California College Health 2000, San Diego State University, San Diego, CA
1995-1997	Research Associate, Battelle Centers for Public Health Research and Evaluation, Seattle, WA
1999-2000	Research Assistant, University of Toronto, Research Services Unit, Toronto, Canada
2001-2003	Researcher, Battelle Centers for Public Health Research and Evaluation, Seattle, WA
2003-2008	Research Scientist, Battelle Centers for Public Health Research and Evaluation, Seattle, WA
2008-Present	Epidemiologist, International Agency for Research on Cancer, Lyon, France

**Other Experience and Professional Memberships**

1989	Research Assistant, University of California, Santa Barbara
1992-1994	Tutor, San Diego State University, McNair Scholars Program
1993	Teaching Assistant, San Diego State University
1998	Statistics Intern, Castings Emissions Reduction Program, Sacramento, CA
1999-2006	Member—American Journal of Public Health
2004-Present	Reviewer—Annals of Family Medicine

**Honors and Scholarships**

1994	Ronald E. McNair Scholarship
2000	University of Toronto Open Fellowship
2001	Ontario Graduate Studentship for Research in Tobacco Control
2002-2001	University of Toronto Doctoral Dissertation Completion Grant

**B. Selected peer-reviewed publications (in chronological order).**

1. Jain, N, Irwin, KL, Montaño, DE, Kasprzyk, D, Carlin, L, **Freeman, C**, Barnes, R, Christian, J, Wolters, C. Family physicians' knowledge of genital human papillomavirus (HPV) infection and HPV-related conditions, United States, 2004. (2006). *Family Medicine*, Jul-Aug;38(7):483-9.
2. Irwin, K, Montaño, DE, Kasprzyk, D, Carlin, L, **Freeman, C**, Barnes, R, Jain, N, Christian, J, Wolters, C. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. (2006). *Obstetrics and Gynecology*, Aug;108(2):397-409.
3. Henderson, Z, Montaño, DE, Kasprzyk, D, Carlin, L, Greek, A, **Freeman, C**, Irwin, K, Barnes, R, Jain, N, Walsh, C. STD Prevention Recommendations and HPV Prevention Opinions of U.S. Adolescent Care

Providers: Results of a National Clinician Survey, 2004. (2006). *Morbidity and Mortality Weekly*, Oct 20;55(41):1117-1120.

4. Jain, N, Irwin, K, Carlin, L, **Freeman, C**, Montano, D, Kasprzyk D. Use of DNA tests for human Papillomavirus infection by US clinicians, 2004. (2007). *Journal of Infectious Disease*, Jul 1;196(1):76-81.
5. Henderson, Z, Irwin, KL, Montaño, DE, Kasprzyk, D, Carlin, L, Greek, A, **Freeman, C**, Barnes, R, Jain, N.
6. Anogenital warts knowledge and counseling practices of US clinicians: results from a national survey. (2007).
7. *Sexually Transmitted Diseases*, Sep;34(9):644-52.
8. Hoover, K, Koumans, EH, Montaño, D, Kasprzyk, D, **Freeman, C**, Greek, A, Jain, N, Irwin, K. Access of Black, Hispanic, and nonprivately insured women to liquid-based cytology, human papillomavirus DNA testing, and on-site colposcopy in the United States. (2009). *Journal of Lower Genital Tract Disease*, Jan;13(1):17-27.

### **Relevant Presentations**

1. Barnes, R., Hsu, K., Freeman, C. "Translating HPV knowledge into practice: Findings from primary care provider interviews." International Society for Sexually Transmitted Disease Research, Ottawa, Ontario, Canada, July, 2003.
2. Cubbins, L.A., Freeman, C., Kasprzyk, D., Montano, D., Woelk, G., NIMH Collaborative HIV/STD Prevention Group. "Seeking Notification of STDS: The Relationship between Alcohol Use, Other Risky Behaviors, and Returning for STD Lab Results in Rural Zimbabwe." Poster presented at the biennial meeting of the *International Society for Sexually Transmitted Disease Research* in Amsterdam, Holland, July 2005.
3. Freeman, C., Cubbins, L.A., Kasprzyk, D., Montano, D., Woelk, G., NIMH Collaborative HIV/STD Prevention Group. "Perceived Health Status among HIV+ Residents in Rural Zimbabwe: The Role of Alcohol, STDs and Community Context." Poster presented at the biennial meeting of the *International Society for Sexually Transmitted Disease Research* in Amsterdam, Holland, July 2005.
4. Freeman, C., Montaño, D., Kasprzyk, D., Carlin, L., Jain, N., Barnes, R., Irwin, K. Knowledge about genital HPV infection and related conditions: Results from a national survey of U.S. health care providers. Presented at the *International Papillomavirus Conference and Clinical Workshop*, Vancouver, British Columbia, April 2005
5. Freeman, C., Kasprzyk, D., Montaño, D., Weaver, B., McPartland, T., Koutsky, L., St. Lawrence, J. HPV: What women know. Presented at the *International Papillomavirus Conference and Clinical Workshop*, Vancouver, British Columbia, April 2005.
6. Irwin, K., Montaño, D., Kasprzyk, D., Carlin, L., Freeman, C., Barnes, R., Jain, N. Cervical cancer screening practices in the United States since the release of National Guidelines on Genital HPV Testing: Results from a national clinician survey, 2004. Presented at the *International Papillomavirus Conference and Clinical Workshop* Vancouver, British Columbia, April 2005.
7. Saraiya, M., Lawson, H., Irwin, K., Carlin, L., Freeman, C., Montaño, D., Kasprzyk, D., Owens, C., Benard, V. HPV and Pap testing practices among clinicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. Presented at the *International Papillomavirus Conference and Clinical Workshop*, Vancouver, British Columbia, April 2005.
8. Ross, LE., Freeman, C., Stroud, LA. African American-White Primary Care Physicians' Prostate Cancer Screening Practices. Poster presented at the *American Sociological Association*, Montreal, Quebec, Canada, August 2006.

### **Technical Reports**

1. Daniel E. Montaño, Danuta Kasprzyk, Linda Carlin, Crystal Freeman, Jeanine Christian. *HPV Clinician Survey: Knowledge, Attitudes, and Practices about Genital HPV Infection and Related Conditions*. Final Report (Contract No. GS23F8167H) submitted to the Centers for Disease Control and Prevention, June 21, 2005.

### **C. Research Support.**

#### **Completed Research Support**

1 R21 AA014802-01 (Lisa A. Cubbins, PI) 9/15/04-8/31/08

NIAAA

“Alcohol, Risky Behavior, and HIV/AIDS in Zimbabwe”

The study examined how the risk of HIV infection is influenced over a 2-year period by: typical alcohol use; behavioral beliefs, attitudes, social norms, protective factors and barriers, and intentions regarding the use of alcohol before sexual behavior; concurrence of alcohol use and sexual behavior; condom use; other individual factors; relationship characteristics; and, community conditions in rural Zimbabwe. The study evaluated the impact of a public opinion leader community-level intervention model on typical alcohol use and other risks for HIV infection over a two-year period. The project also investigated how HIV/AIDS disease progression is affected by typical alcohol use, co-morbidities (HBV, HCV, STIs), other individual factors, family support, health care use, and community characteristics over a two-year period.

Role: Co-investigator

T01545T (Danuta Kasprzyk, PI) 1/01/02-12/31/05

HHS CDC/Washington State Health Department/University of Washington

Formative and Survey Research to Aid in the Development of Educational Messages Regarding a Diagnosis of HPV

The aim of this study is to assess the psycho-social effects of a diagnosis of high risk Human Papillomavirus (HPV), after an abnormal Pap screening result. This study was conducted in three phases: 1) a formative questionnaire development phase; 2) an instrument design and pretesting phase and 3) a survey of women enrolled in a Seattle-King County HPV surveillance program. The formative questionnaire design phase consisted of conducting focus groups of women who come in for a routine Pap screening visit, and are tested for HPV. Women with positive or negative diagnoses of high risk HPV were recruited into the formative study. Eight focus groups were conducted with African American, Hispanic, and White women to ask them to describe their reactions to their HPV diagnosis. Qualitative data were transcribed and content analyzed to develop the quantitative survey instrument. The survey instrument was pretested with a sample of 30 women and psychometric properties were assessed. After these results, the instrument was used in a survey of 150-250 women stratified by their Pap and HPV results to document women's reactions to their diagnoses. Results to the survey were used to design educational messages to ameliorate the negative effects of an HPV diagnosis.

Role: Researcher

GS-23F-8167H/ORDER No. 0000166390/SIN 874- 9/17/01-4/30/06

3/CPHRE IOT (Daniel E. Montaño, PI)

CDC, Division of STD Prevention

National Survey of Human Papilloma Virus (HPV) Detection, Management, Infection Control, and Prevention Practices Among Primary Care Clinicians

This study conducted a national sample survey of physicians, nurse practitioners, and physician's assistants (N = 7,000) to determine current clinical practices regarding high and low risk Human Papillomavirus (HPV) in primary care settings. The national survey was conducted among these clinician groups to describe their practices regarding the detection, diagnosis, treatment, infection control, prevention, clinical, and partner management practices regarding HPV among their primary care patients. Development and pretesting of the survey instrument was conducted in Phase 1 over a 6 month period. Implementation of the survey was done in Phase 2, over a 12 month period. Data processing, analysis, report writing and publication preparation occurred in Phase 3, over an 18 month period. Results of this survey were used to design educational programs for clinicians regarding HPV diagnosis and prevention in primary care settings.

Role: Researcher

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Galichet, Laurent Yves</b>		POSITION TITLE	
eRA COMMONS USER NAME (credential, e.g., agency login)		Editor, <i>IARC Monographs</i> programme	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Manchester University, Manchester, UK	BS	1997	Chemistry
University of Aberdeen, Aberdeen, UK	MS	1998	Analytical chemistry

**A. Positions and Honors**

**Employment**

1998-1998 Analytical Chemist, General Electric Plastics, Bergen op Zoom, The Netherlands  
 1999-2001 New Product Development Chemist, Martindale Pharmaceuticals, Romford, UK  
 2001-2001 Patent Analyst, Derwent Information, London, UK  
 2001-2006 Managing Editor, The Royal Pharmaceutical Society of Great Britain, London, UK  
 2006-2006 Editor, Medicus-Publicis, London, UK  
 2007-2008 Freelance Medical Writer/Editor, London, UK  
 2008-present Editor, *IARC Monographs* programme, International Agency for Research on Cancer, Lyon, France

**B. Selected peer-reviewed publications**

Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Guha N, Freeman C, **Galichet L**, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. *Lancet Oncol* 10: 453-454.

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, **Galichet L**, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens--Part B: biological agents. *Lancet Oncol* 10: 321-322.

Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, **Galichet L**, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens-Part A: pharmaceuticals. *Lancet Oncol* 10:13-14.

Galichet LY (2006). Alitame. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 28-29.

Galichet LY (2006). Aluminium Oxide. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 38-39.

Galichet LY (2006). Aluminium Stearate. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 42-43.

Galichet LY (2006). Cellulose, Microcrystalline. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 132-135.

Program Director/Principal Investigator (Last, First, Middle): COGLIANO, Vincent James

Galichet LY (2006). Cresol. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 208-210.

Galichet LY (2006). Iron Oxides. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 364-365.

Galichet LY (2006). Myristic Acid. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 484-485.

Galichet LY (2006). Oleyl Alcohol. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 496-497.

Galichet LY (2006). Palmitic Acid. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 501-502.

Galichet LY (2006). Sodium Phosphate, Monobasic. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 696-698.

Galichet LY (2006). Starch. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 725-730.

Galichet LY (2006). Water. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 802-806.

Galichet LY (2006). Zinc Acetate. In: Rowe RC, Sheskey PJ, Owen SC, eds. *Handbook of Pharmaceutical Excipients*. London: Pharmaceutical Press, 830-831.

Moffat AC, Osselton MD, Widdop B, Galichet LY, eds (2004). *Clarke's Analysis of Drugs and Poisons*. London: Pharmaceutical Press.

**C. Research support**

N/a

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>GUHA, Neela</b>		POSITION TITLE <b>Scientist</b>	
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of California, Berkeley	Ph.D.	2009	Epidemiology
University of California, Berkeley	M.P.H.	2004	Epidemiology/Biostatistics
University of California, Berkeley	B.A.	2000	Molecular and Cell Biology, Genetics

**A. Positions and Honors**

**Positions and Employment**

2008-present Scientist, International Agency for Research on Cancer, Lyon, France  
 2005-2008 Graduate Student Researcher, University of California at Berkeley  
 2007-2007 Graduate Student Instructor, University of California at Berkeley  
 2007-2007 Research Fellow, Kaiser Permanente Division of Research, Oakland, CA  
 2004-2005 Special Training Awardee, International Agency for Research on Cancer, Lyon, France  
 2003-2003 Researcher, California Department of Health Services, Environmental Health Investigations Branch, Oakland, CA  
 2002-2004 Graduate Student Researcher, University of California at Berkeley  
 2000-2002 Staff Research Associate, Dept. of Surgical Oncology, University of California at San Francisco

**Other Experience and Professional Memberships**

2000-2000 Research Assistant, University of California at Berkeley Sequencing Facility  
 1999-2000 Research Assistant, Lawrence Berkeley National Laboratory, Berkeley, CA  
 1998-1999 Research Assistant, Dept. of Surgical Oncology, University of California San Francisco  
 2007-2008 Member, European Association of Cancer Research

**Honors**

2008 Russell M. Grossman Endowment  
 2007 Kaiser Permanent-UCB Center for Health Research Fellowship  
 2006 Susan Kersch DeYoung Memorial Scholarship  
 2004 Special Training Award, International Agency for Research on Cancer

**B. Selected peer-reviewed publications (in chronological order)**

1. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, **Guha N**, Freeman C, Galichet L, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. *Lancet Oncol.* 2009 May;10(5):453-4.
2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, **Guha N**, Freeman C, Galichet L, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. *Lancet Oncol.* 2009 Apr;10(4):321-2.

Program Director/Principal Investigator (Last, First, Middle): COGLIANO, Vincent James

3. **Guha N**, Kwan ML, Quesenberry CP Jr, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. *Breast Cancer Res Treat.* 2009 Feb 17.
4. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, **Guha N**, Galichet L, Coglianò V; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part A: pharmaceuticals. *Lancet Oncol.* 2009 Jan;10(1):13-4.
5. **Guha N**, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. *Am J Epidemiol.* 2008 Dec 1;168(11):1221-32.
6. Coglianò V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Lamia Benbrahim-Tallaa, **Guha N**. Future priorities for IARC monographs. *Lancet Oncol.* 2008 Aug;9(8):708.
7. **Guha N**, Boffetta P, Wünsch Filho V, Eluf Neto J, Shangina O, Zaridze D, Curado MP, Koifman S, Matos E, Menezes A, Szeszenia-Dabrowska N, Fernandez L, Mates D, Daudt AW, Lissowska J, Dikshit R, Brennan P. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. *Am J Epidemiol.* 2007 Nov 15;166(10):1159-73.
8. Arvold ND\*, **Guha N**\*, Wang D, Matli M, Deen DF, Warren RS, Haas-Kogan DA. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. *Int J Radiat Oncol Biol Phys.* 2005 May 1;62(1):207-12. \*co-authors contributed equally to this work

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Benbrahim-TALLAA Lamia</b>		POSITION TITLE <b>Scientist</b>	
eRA COMMONS USER NAME <b>(b) (4)</b>			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
National Cancer Institute at NIEHS INSERM/ Claude Bernard University (Lyon I), France	Postdoc	2007	Inorganic Carcinogenesis
Claude Bernard University (Lyon I), France	Ph.D.	2001	Reproductive Toxicology
Claude Bernard University (Lyon I), France	Master	1997	Metabolism, Endocrinology, and Nutrition
Claude Bernard University (Lyon I), France	Bachelor	1996	Physiology, Endocrinology, and Metabolic Regulations
Houari Boumedienne University, Algiers, Algeria	Bachelor	1991	Endocrinology

**A. Positions and Honors**

Positions and Employment

July - September 1997 Summer Intern, Department of Physiology, Claude Bernard University, Lyon, France.

09/1997 - 07/2001 Graduate Student Researcher, Reproductive Toxicology Graduate Program, National Institute of Science and Medical Research (INSERM U407), France.

10/1999 - 10/2000 Laboratory Assistant, Environmental Toxicology Graduate Program, INSERM U407, Lyon, France.

07/2002 ~ 07/2007 Postdoctoral Fellow, Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at National Institute of Environmental Health and Science, Research Triangle Park, NC.

09/2007 ~ Present Scientist, IARC Monographs section, International Agency of Research on Cancer/ World Health Organization, Lyon, France.

Other Experience

2003 - 2007 English to French translation for *Environmental Health Perspectives*, National Institute of Environmental Health and Science, Research Triangle Park, NC.

2009 and until 2012 Member of the Editorial Board of *Toxicology and Applied Pharmacology*.

Professional Memberships

2002 – Present Member, Society of Toxicology (SOT).

2003 - Present Member, North Carolina Society of Toxicology (SOT).

Honors

03/1999 Student Certificate of Excellence for best poster presentation, French Society of Andrology (SALF) 9<sup>th</sup> Annual Meeting, Paris, France.

03/2004 Poster of Merit (CCR-FYI Annual Retreat 2004), Postdoc National Cancer Institute Annual Retreat, Frederick, MD.

- 03/2005 Carcinogenesis Specialty Section 1<sup>st</sup> place award for a Postdoctoral Student for Research Excellence in Carcinogenesis. Society of Toxicology (SOT) 44th Annual Meeting, New Orleans, LA.
- 03/2006 Metal Specialty Section 3<sup>rd</sup> place award for a Postdoctoral Student for Research Excellence in Metal Carcinogenesis. Society of Toxicology (SOT) 45th Annual Meeting, San Diego, CA.
- 03/2007 Mechanisms Specialty Section MERCK Postdoctoral Award for Meritorious Research. Society of Toxicology (SOT) 46th Annual Meeting, Charlotte, NC.

#### B. Selected peer-reviewed publications (in chronological order)

- 1- **Benbrahim-Tallaa L**, Tabone E, Tosser-Klopp G, Hatey F and Benahmed M. Glutathione S-transferase alpha expressed in porcine sertoli cells is under the control of follicle stimulating hormone and testosterone. *Biol. Reprod.* 2002; 66:1734-1742.
- 2- **Benbrahim Tallaa L**, Boussouar F, Rey C, Benahmed M. Tumor necrosis factor- $\alpha$  inhibits glutathione S-transferase alpha (GST $\alpha$ ) expression in cultured porcine sertoli cells. *J. Endocrinol* 2002; 175:803-812.
- 3- **Benbrahim-Tallaa L**, Waterland RA, Webber MM and Waalkes MP. Molecular Events Associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. *Toxicol Appl Pharmacol.* 2005; 206:288-298.
- 4- **Benbrahim-Tallaa L**, Webber MM and Waalkes MP. Acquisition of androgen-independence in human prostate epithelial cells during arsenic-induced malignant transformation. *Environ Health Perspect* 2005; 113:1134-1139. [**note: Manuscript highlighted in Science Selections section**].
- 5- Liu J, **Benbrahim-Tallaa L**, Qian X, Yu L, Xie Y, Boos J, Qu W, Waalkes MP. Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL 1215 cells. *Toxicol Appl Pharmacol.* 2006; 216:407-415.
- 6- **Benbrahim-Tallaa L**, Liu J, Webber MM and Waalkes MP. Role of estrogen receptor and disturbed androgen metabolism in acquired androgen independence during cadmium-induced malignant transformation. *The Prostate* 2007; 67:135-145.
- 7- **Benbrahim-Tallaa L**, Webber MM and Waalkes MP. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. *Environ Health Perspect* 2007; 115:143-147.
- 8- Xie Y, Liu J, **Benbrahim-Tallaa L**, Ward JM, Logston D, Diwan BA, Waalkes MP. Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. *Toxicology.* 2007; 236:7-15.
- 9- **Benbrahim-Tallaa L**, Waterland RA, Webber MM and Waalkes MP. Tumor Suppressor Gene Inactivation During Cadmium-induced malignant transformation of human prostate cells correlates with over-expression of *de novo* DNA methyltransferase. *Environ Health Perspect* 2007; 115:1454-1459.
- 10- Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, **Benbrahim-Tallaa L**, Cogliano V. Carcinogenicity of shift-work, painting, and fire-fighting. *Lancet oncol.* 2007; 8:1065-1066.
- 11- **Benbrahim-Tallaa L**, Siddeek B, Bozec A, Tronchon V, Florin A, Friry C, Tabone E, Mauduit C, and Benahmed M. Alterations of Sertoli cell activity in the long-term testicular germ cell death process induced by fetal androgen disruption *J. Endocrinol* 2008 196:21-31.

Program Director/Principal Investigator (Last, First, Middle): **COGLIANO, Vincent James**

- 12- **Benbrahim-Tallaa L** and Waalkes MP. Inorganic arsenic and prostate cancer. *Environ Health Perspect* 2008; 116:158-164.
- 13- Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, **Benbrahim-Tallaa L** and Coglianov V. Carcinogenicity of some aromatic amines, organic dyes, and related exposures. *Lancet oncol*. 2008; 9:322-323.
- 14- Coglianov V, Baan R, Straif K, Yann Grosse, Secretan B, El Ghissassi F, Bouvard V, **Benbrahim-Tallaa L** and Guha N. Future priorities for IARC Monographs. *Lancet oncol*. 2008; 9:699-808.
- 15- Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, **Benbrahim-Tallaa L**, Guha N, Galichet L, Coglianov V. A review of human carcinogens—Part A: pharmaceuticals. *Lancet oncol* 2009;10:13-14.
- 16- **Benbrahim-Tallaa L** and Waalkes MP. Inorganic arsenic and prostate cancer. *Cien Saude Colet*. 2009;14:307-318.
- 17- Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, **Benbrahim-Tallaa L**, Guha N, Galichet L, Coglianov V. A review of human carcinogens—Part B: biological Agents. *Lancet oncol* 2009; 10:321-322.
- 18- Straif K, **Benbrahim-Tallaa L**, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Guha N, Galichet L, Coglianov V. A review of human carcinogens—Part B: biological Agents. *Lancet oncol* 2009; 10:453-454.
- 19- **Benbrahim-Tallaa L**, Tokar EJ, Bhalchandra AD, Dill AL, Coppin JF, Waalkes MP. Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype. *Environ Health Perspect* [Accepted]

### C. Research Support

None

Program Director/Principal Investigator (Last, First, Middle): **COGLIANO, Vincent James**

<b>PROGRESS REPORT SUMMARY</b>	GRANT NUMBER 5U01CA033193-27	
	PERIOD COVERED BY THIS REPORT	
PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR COGLIANO, Vincent James	FROM 1 Sept 2008	THROUGH 31 Aug 2009
APPLICANT ORGANIZATION International Agency for Research on Cancer		
TITLE OF PROJECT (Repeat title shown in Item 1 on first page) Evaluation of Carcinogenic Risks to Humans		
A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
C. Select Agent Research	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
D. Multiple PD/PI Leadership Plan	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change

SEE PHS 2590 INSTRUCTIONS.

**WOMEN AND MINORITY INCLUSION: See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.**

**a. Specific Aims**

The aim of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, physical agents, biological agents, occupational exposures, and lifestyle factors. International, interdisciplinary Working Groups of expert scientists develop the critical reviews and evaluations, which are published in the IARC Monographs series.

**b. Studies and Results**

IARC convened meetings to develop four new volumes of Monographs (Volume 100, Parts A-D) and is preparing for two meetings (Volume 100, Parts E-F) that will be convened during the next budget period (Sept 2009 to Aug 2010). These six volumes are updating the Monographs on the more than 100 agents that had been classified as carcinogenic to humans (Group 1) in Volumes 1-99. Some highlights from each new volume include:

Part A: Pharmaceuticals (23 agents, Oct 2008).

Highlights: estrogen-only menopausal therapy was identified as a cause of ovarian cancer; aristolochic acid (present in some weeds in grain fields in some Balkan countries) was newly identified as carcinogenic to humans (Grosse et al 2008).

Agents classified in Group 1: diethylstilboestrol, estrogen-only menopausal therapy, estrogen-progestogen oral contraceptives, estrogen-progestogen menopausal therapy, tamoxifen, busulfan, chlorambucil, etoposide, etoposide in combination with cisplatin and bleomycin, melphalan, MOPP and other combined chemotherapy including alkylating agents, semustine (methyl-CCNU), thiotepa, treosulfan, aristolochic acid, plants containing aristolochic acid, azathioprine, chlornaphazine, cyclosporine, cyclophosphamide, 8-Methoxypsoralen (Methoxsalen) plus ultraviolet radiation, phenacetin, analgesic mixtures containing phenacetin.

**Part B: Biological Agents** (17 agents, Feb 2009).

**Highlights:** a system to classify the carcinogenicity of human papillomavirus types based on prevalence and phylogenetic analogy was developed; Epstein-Barr virus (which infects virtually everyone) may have a role in 5-10% of gastric cancer worldwide; hepatitis C virus was identified as a cause of non-Hodgkin lymphoma, *Clonorchis sinensis* (a liver fluke endemic in parts of China) and Kaposi sarcoma herpes virus were newly classified as *carcinogenic to humans* (Bouvard et al 2009).

**Agents classified in Group 1:** Epstein-Barr virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus (type 1), human papillomavirus (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), human T-cell lymphotropic virus (type 1), Kaposi sarcoma herpes virus, Clonorchis sinensis, Helicobacter pylori, Opisthorchis viverrini, Schistosoma haematobium.

**Other agents:** Group 2A: human papillomavirus (type 68); Group 2B: human papillomavirus types 26, 53, 66, 67, 70, 76, 82; types 30, 34, 69, 85, 97; types 5, 8), Group 3: human papillomavirus (types 6, 11).

**Part C: Metals, Arsenic, Dusts and Fibres** (15 agents, Mar 2009).

**Highlights:** all forms of asbestos were confirmed as *carcinogenic to humans* (Group 1) [the previous full *Monograph* had been published in 1977]; asbestos was identified as a cause of ovarian cancer; leather dust was newly classified as *carcinogenic to humans*, and the organic arsenical pesticides DMA and MMA were newly classified as *possibly carcinogenic* (Straif et al 2009).

**Agents classified in Group 1:** arsenic and its inorganic compounds, beryllium and its compounds, cadmium and its compounds, chromium[VI] compounds, nickel compounds; asbestos (chrysotile, crocidolite, amosite, tremolite, actinolite, anthophyllite), erionite, leather dust, silica dust (crystalline, in the form of quartz or cristobalite), wood dust.

**Other agents:** Group 2B: dimethylarsinic acid, monomethylarsonic acid.

**Part D: Radiation** (18 agents, June 2009).

**Highlights:** use of artificial tanning devices, and all ultraviolet radiation in general, were newly classified as *carcinogenic to humans* (Group 1); indoor radon is responsible for 10% of lung cancer (the leading cause of lung cancer after tobacco smoke); *in-utero* exposure to X-rays increases the risk of cancer in childhood and in adult life; there is *sufficient evidence* of ocular melanoma in welders (previous assessments focused on metal and chemical fumes).

**Agents classified in Group 1:** alpha-particle-emitting radionuclides (internally deposited), radon-222 and decay products, haematite mining (underground) with exposure to radon, radium-224 and decay products, radium-226 and decay products, radium-228 and decay products, thorium-232 and decay products, plutonium; beta-particle-emitting radionuclides (internally deposited), fission products (including strontium-90), phosphorus-32 (as phosphate), radioiodines (including iodine-131); neutron radiation; X-rays and gamma-rays; ionizing radiation (all types); solar radiation, ultraviolet radiation (bandwidth 100-400 nm, encompassing UVC, UVB and UVA), ultraviolet-emitting tanning devices.

**Other agents:** welding.

IARC is making the full text of all *Monographs* freely available on the *Monographs* programme website (<http://monographs.iarc.fr/>). All volumes published since Volumes 57 (1993) are now available and the rest will be added as soon as they are scanned and formatted. This has resulted in a 20-fold increase in the amount of information downloaded compared with the time before December 2007, when full text was made available for some *Monographs* for the first time. Currently, the *Monographs* programme website is visited every month by people from more than 120 countries.

d. **Plans.** During the next budget period (Sept 2009 to Aug 2010), IARC will convene two more expert Working Groups to update the *Monographs* on the remaining Group 1 agents identified in Volumes 1-99:

**Volume 100, Part E: Lifestyle factors** (11 agents, 29 Sept–6 Oct 2009).

**Volume 100, Part F: Chemical agents and Related Occupations** (34 agents, 20-27 Oct 2010).

IARC will then focus attention on checking the backlogged volumes and preparing them for publication. IARC will also complete the posting of all *Monographs* volumes (since Volume 1) and supplements on its website.

**e. Publications**

IARC (2008) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Volume 97, 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide). Freely available at <http://monographs.iarc.fr/ENG/Monographs/vol97/index.php>

Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Coglianò V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens – Part A: pharmaceuticals. *Lancet Oncology* 10(1): 13-14, freely available at <http://download.thelancet.com/pdfs/journals/lanonc/PIIS1470204508702869.pdf?id=aeaa5a245ca1fdbb:6547e93d:1213626ddd3:-30991242156074972>

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglianò V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens – Part B: biological agents. *Lancet Oncology* 10(4): 321-322, freely available at <http://download.thelancet.com/pdfs/journals/lanonc/PIIS1470204509700968.pdf?id=aeaa5a245ca1fdbb:6547e93d:1213626ddd3:-30991242156074972>

Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Guha N, Freeman C, Galichet L, Coglianò V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens – Part C: metals, arsenic, dusts, and fibres. *Lancet Oncology* 10(5): 453-454, freely available at <http://download.thelancet.com/pdfs/journals/lanonc/PIIS1470204509701342.pdf?id=aeaa5a245ca1fdbb:6547e93d:1213626ddd3:-30991242156074972>

El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglianò V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens – Part D: radiation. *Lancet Oncology* 10(8) (in preparation)

Coglianò V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N (2008) Future priorities for IARC Monographs. *Lancet Oncology* 9(8): 708

Coglianò VJ, Baan RA, Straif K, Grosse Y, Secretan B, El Ghissassi F (2008) Use of mechanistic data in IARC evaluations. *Environmental and Molecular Mutagenesis* 49(2): 100-109

Program Director/Principal Investigator (Last, first, middle): **COGLIANO, Vincent James**

GRANT NUMBER  
**5U01CA033193-27**

### CHECKLIST

**1. PROGRAM INCOME (See instructions.)**

All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

**2. ASSURANCES/CERTIFICATIONS (See instructions.)**

In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398, and listed in Part I, 4.1 under Item 14. If unable to certify compliance, where applicable, provide an explanation and place it after the Progress Report (Form Page 5).

**3. FACILITIES AND ADMINISTRATIVE (F&A) COSTS**

Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will **not** be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

DHHS Agreement dated: \_\_\_\_\_  No Facilities and Administrative Costs Requested.

No DHHS Agreement, but rate established with J.W. Berry, Accountant, DHHS Date 10/18/1983

**CALCULATION\***

Entire proposed budget period: Amount of base \$ 718,649 x Rate applied 13.00 % = F&A costs \$ 93,424

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

\*Check appropriate box(es):

Salary and wages base  Modified total direct cost base  Other base (Explain)

Off-site, other special rate, or more than one rate involved (Explain)

Explanation (Attach separate sheet, if necessary.):

Rate applied to direct costs

**SENIOR/KEY PERSONNEL REPORT**

**GRANT NUMBER**  
5U01CA033193-27

Place this form at the end of the signed original copy of the application. Do not duplicate.

**All Key Personnel for the Current Budget Period (do not include Other Significant Contributors)**

Name	Degree(s)	SSN (last 4 digits)	Role on Project (e.g. PD/PI, Res. Assoc.)	Months Devoted to Project		
				Cal	Acad	Summer
Cogliano, Vincent	PhD	(b)(6)	PI	(b)(4), (b)(6)		
Baan, Robert	PhD	N/A	Scientist	(b)(4), (b)(6)		
Benbrahim-Tallaa, Lamia	PhD	N/A	Scientist	(b)(4), (b)(6)		
Bouvard, Véronique	PhD	N/A	Scientist	(b)(4), (b)(6)		
El Ghissassi, Fatiha	PhD	N/A	Scientist	(b)(4), (b)(6)		
Freeman, Crystal	PhD	(b)(6)	Scientist	(b)(4), (b)(6)		
Galichet, Laurent	MS	N/A	Editor	(b)(4), (b)(6)		
Grosse, Yann	PhD	N/A	Scientist	(b)(4), (b)(6)		
Guha, Neela	PhD	(b)(6)	Scientist	(b)(4), (b)(6)		
Secretan, Béatrice	PhD	N/A	Scientist	(b)(4), (b)(6)		
Straif, Kurt	MD, PhD	N/A	Scientist	(b)(4), (b)(6)		



**INTERNATIONAL AGENCY FOR RESEARCH ON CANCER  
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER**

150 cours Albert Thomas, 69372 Lyon cedex 08, France <http://www.iarc.fr>

IARC Monographs  
Tel.: +33 4 72 73 85 07  
Fax: +33 4 72 73 83 19  
E-mail: [imo@iarc.fr](mailto:imo@iarc.fr)  
<http://monographs.iarc.fr>

Division of Extramural Activities  
Support, OER  
National Institutes of Health  
6705 Rockledge Drive, Room 2207,  
MSC 7987  
Bethesda, MD 20817  
USA

Special courier: tel. 1-301-594.6584

Ref.:

23 June 2009

Dear Sirs,

I enclose our Grant Progress Report 5U01CA033193-27 for the budget period from 1 September 2008 to 31 August 2009, including the budget request of the next period from 1 September 2009 to 31 August 2010.

I trust the enclosed report is satisfactory and look forward to our continued collaboration.

Yours sincerely,

Vincent James Cogliano  
Head, Section of IARC Monographs

ENCL: As mentioned